Health Dictionary Find a Doctor

Hypersensitivity pneumonitis

For patient information, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis (EAA), is not a single disease but is a complex syndrome of varying intensity, clinical presentation, and natural history.

The syndrome was first described in Iceland in 1874 and termed heykatarr. The syndrome is caused by sensitization to repeated inhalation of dusts containing one of 300 organic antigens. These organic dusts come from a wide variety of sources but most commonly include:

  • Dairy and grain products
  • Animal dander and protein
  • Wood bark
  • Water reservoir vaporizers

The two most common antigens are:

  1. Thermophilic actinomycetes and
  2. Avian proteins

As a rseult of exposure to thee antigens, the two most common causes (i.e. diseases) are:

  1. Farmer’s lung and
  2. Bird fancier’s lung

Pathologically, the HP syndrome is associated with diffuse inflammation of lung parenchyma and airways.

Based on the length and intensity of exposure and subsequent duration of illness, there are 3 clinical presentations of HP:

  1. Acute
  2. Subacute (intermittent)
  3. Chronic progressive

Synonyms and related keywords: hypersensitivity pneumonitis, HP, bird fancier’s lung, extrinsic allergic alveolitis, farmer’s lung, Saccharopolyspora rectivirgula, S rectivirgula, Micropolyspora faeni, M faeni, Thermoactinomyces sacchari, T sacchari, Thermoactinomyces vulgaris, T vulgaris, Penicillium casei, P casei, Aspergillus clavatus, A clavatus, Mucor stolonifer, M stolonifer, Sitophilus granarius, S granarius, Cladosporium, heykatarr, bagassosis, grain handler’s lung, humidifier lung, air-conditioner lung, bird breeder’s lung, cheese worker’s lung, malt worker’s lung,paprika splitter’s lung, mollusk shell hypersensitivity, chemical worker’s lung, pulmonary disease, lung disease.

Historical Perspective

  • [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
  • In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
  • In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
  • [group1]
  • [group2]
  • [group3]
  • Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

  • The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
  • The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
  • On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Causes

  • [Disease name] may be caused by either [cause1], [cause2], or [cause3].
  • [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
  • There are no established causes for [disease name].

Differentiating [disease name] from other Diseases

  • [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
  • [Differential dx1]
  • [Differential dx2]
  • [Differential dx3]

Epidemiology and Demographics

  • The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
  • In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

  • Patients of all age groups may develop [disease name].
  • [Disease name] is more commonly observed among patients aged [age range] years old.
  • [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected with [disease name] than [gender 2].
  • The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

  • There is no racial predilection for [disease name].
  • [Disease name] usually affects individuals of the [race 1] race.
  • [Race 2] individuals are less likely to develop [disease name].

Risk Factors

  • Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

  • The majority of patients with [disease name] remain asymptomatic for [duration/years].
  • Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
  • If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
  • Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
  • Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

  • The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
  • [criterion 1]
  • [criterion 2]
  • [criterion 3]
  • [criterion 4]

Symptoms

  • [Disease name] is usually asymptomatic.
  • Symptoms of [disease name] may include the following:
  • [symptom 1]
  • [symptom 2]
  • [symptom 3]
  • [symptom 4]
  • [symptom 5]
  • [symptom 6]

Physical Examination

  • Patients with [disease name] usually appear [general appearance].
  • Physical examination may be remarkable for:
  • [finding 1]
  • [finding 2]
  • [finding 3]
  • [finding 4]
  • [finding 5]
  • [finding 6]

Laboratory Findings

  • There are no specific laboratory findings associated with [disease name].
  • A [positive/negative] [test name] is diagnostic of [disease name].
  • An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
  • Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

  • There are no [imaging study] findings associated with [disease name].
  • [Imaging study 1] is the imaging modality of choice for [disease name].
  • On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
  • [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

  • [Disease name] may also be diagnosed using [diagnostic study name].
  • Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

  • There is no treatment for [disease name]; the mainstay of therapy is supportive care.
  • The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
  • [Medical therapy 1] acts by [mechanism of action 1].
  • Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

  • Surgery is the mainstay of therapy for [disease name].
  • [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
  • [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

  • There are no primary preventive measures available for [disease name].
  • Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
  • Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

References

Template:Respiratory pathology


Template:WikiDoc Sources

Historical Perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

Hypersensitivity pneumonitis was first discovered more than a 100 years ago. It was called “bird fancier’s lung”.In 1960s, etiology and immune mechanism was described by Dr Jack Pepys. In 1977, Dr Peter C Warren described the pathogenesis of hypersensitivity pneumonitis in detail. Dr Hubert Reynolds from Hershey, Pennsylvania, USA described the relation between inflammatory lymphocytes in the lungs and hypersensitivity pneumonitis.In 1990, Dr Marc Lalancette, a medical student of Laval found that permanent lung damage occurs in farmers suffering from hypersensitivity pneumonitis due to emphysema.

Historical Perspective

Discovery

  • Hypersensitivity pneumonitis was first discovered more than a 100 years ago and was called bird fancier’s lung.[1]
  • In 1960s, etiology and immune mechanism was described by Dr Jack Pepys.[2]
  • In 1977, Dr Peter C Warren from University of Manitoba, Winnipeg, Manitoba described the pathogenesis of hypersensitivity pneumonitis in detail.[3]
    • He was the first to report that cigarette smokers were exposed to a farmer lung antigen called Saccharopolyspora rectivirgula ( then called Micropolysporafaeni), had very low levels of antibodies against this bacteria in their serum.
  • The association between increased number of inflammatory lymphocytes in the lungs and hypersensitivity pneumonitis was made by Dr Hubert Reynolds from Hershey, Pennsylvania, USA.
  • In 1990, Dr Marc Lalancette, a medical student of Laval found that permanent lung damage occurs in farmers suffering from hypersensitivity pneumonitis due to emphysema. [4]

References

  1. Campbell JM. Acute symptoms following work with hay. BMJ. 1932;2:1143–4
  2. PEPYS J, JENKINS PA, FESTENSTEIN GN, GREGORY PH, LACEY ME, SKINNER FA (1963). “FARMER’S LUNG. THERMOPHILIC ACTINOMYCETES AS A SOURCE OF “FARMER’S LUNG HAY” ANTIGEN”. Lancet. 2 (7308): 607–11. PMID 14054440.
  3. Warren CP (1977). “Extrinsic allergic alveolitis: a disease commoner in non-smokers”. Thorax. 32 (5): 567–9. PMC 470791. PMID 594937.
  4. Lalancette M, Carrier G, Laviolette M, Ferland S, Rodrique J, Bégin R, Cantin A, Cormier Y (1993). “Farmer’s lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors”. Am. Rev. Respir. Dis. 148 (1): 216–21. doi:10.1164/ajrccm/148.1.216. PMID 8317802.
Classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

The clinical presentations of hypersensitivity pneumonitis depend on the frequency, length, exposure, and duration of illness. Due to a lot of variation in the the presentation hypersensitivity pneumonitis has been classified according to various schemes. Hypersensitivity pneumonitis may be classified into several subtypes based on various classifications methods such as classical classification, boyd classification, cormier classification, and selman classification.

Classification

  • The clinical presentations of hypersensitivity pneumonitis depend on:
    • Frequency
    • Length
    • Exposure
    • Duration of illness
  • Due to a lot of variation in the the presentation hypersensitivity pneumonitis has been classified according to various schemes.
  • Hypersensitivity pneumonitis may be classified into several subtypes based on:
    • Classical classification:
      • Acute
        • Abrupt in onset.
        • Occurs after heavy exposure to antigen.
        • Symptoms can be confused with bacterial or viral infection.
        • On auscultation diffuse crackles and tachypnea are notable.
        • Histopathology reveals non-caseating interstitial granulomas with giant cells. 
      • Subacute
        • Gradual in onset.
        • Symptom like cough, fatigue, weightloss, and dyspnea may be seen.
        • Removal of exposure leads to complete resolution.
        • On auscultation diffuse crackles and tachypnea may be seen.
        • Histopathology reveals more well formed non-caseating interstitial granulomas and interstitial fibrosis.
      • Chronic
        • Insidious in onset with history of acute episodes.
        • Digital clubbing may be seen. [1]
        • Pulmonary fibrosis leads to disabling and irreversible respiratory symptoms.[2]
    • Boyd classification:[3]
      • Acute progressive
        • Severe symptoms occur after exposure to antigen.
        • Recurrent exposure leads to symptom progression.
        • Clinically patients are pyrexial with bilateral crackles on chest auscultation.
        • Patients may require hospitalization due to respiratory compromise.
      • Acute intermittent nonprogressive
        • Similar to acute progressive disease but less intense.
        • Patients feel well in between episodes.
        • Subsequent exposure leads to less severe symptoms.
        • Patients are clinically stable in the long run.
        • Pulmonary inflammatory response deteriorates with recurrent exposure to the antigen.[4]
      • Chronic progressive disease
        • Occurs after recurrent acute episodes or insidiously.[5]
        • Patients are diagnosed in the late stages.
        • Only clue for diagnosis is antigen exposure.
        • Patients often present with permanent disability in the form of pulmonary fibrosis or respiratory failure.
        • Disease is not reversed even after antigen exposure is avoided. [6]
      • Subclinical disease
        • Patients are immunological sensitized but are asymptomatic.
        • Patients with recurrent exposure to antigens may convert to chronic form.
    • Cormier classification:
      • Active
      • Residual
    • Selman classification:
      • Active non-progressive and intermittent
      • Acute progressive and intermittent
      • Chronic
        • Nonprogressive
        • Progressive

References

  1. Sansores R, Salas J, Chapela R, Barquin N, Selman M (1990). “Clubbing in hypersensitivity pneumonitis. Its prevalence and possible prognostic role”. Arch. Intern. Med. 150 (9): 1849–51. PMID 2393316.
  2. Vourlekis JS, Schwarz MI, Cherniack RM, Curran-Everett D, Cool CD, Tuder RM, King TE, Brown KK (2004). “The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis”. Am. J. Med. 116 (10): 662–8. doi:10.1016/j.amjmed.2003.12.030. PMID 15121492.
  3. Walls AF, Bennett AR, Godfrey RC, Holgate ST, Church MK (1991). “Mast cell tryptase and histamine concentrations in bronchoalveolar lavage fluid from patients with interstitial lung disease”. Clin. Sci. 81 (2): 183–8. PMID 1653661.
  4. Bourke SJ, Banham SW, Carter R, Lynch P, Boyd G (1989). “Longitudinal course of extrinsic allergic alveolitis in pigeon breeders”. Thorax. 44 (5): 415–8. PMC 461848. PMID 2763241.
  5. Fink JN, Sosman AJ, Barboriak JJ, Schlueter DP, Holmes RA, Ohtani Y, Saiki S, Sumi Y, Inase N, Miyake S, Costabel U, Yoshizawa Y (1968). “Pigeon breeders’ disease. A clinical study of a hypersensitivity pneumonitis”. Ann. Intern. Med. 68 (6): 1205–19. doi:10.1016/S1081-1206(10)61863-7. PMID 4231667.
  6. Fink JN, Sosman AJ, Barboriak JJ, Schlueter DP, Holmes RA (1968). “Pigeon breeders’ disease. A clinical study of a hypersensitivity pneumonitis”. Ann. Intern. Med. 68 (6): 1205–19. PMID 4231667.
Pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hypersensitivity pneumonitis involves inhalation of organic dusts which act as an antigen. This leads to an exaggerated immune response, which is called hypersensitivity reactions. In hypersensitivity pneumonitis, its either Type III hypersensitivity or type IV hypersensitivity.

Pathophysiology

Acute HP

There are noncaseating interstitial granulomas and mononuclear cell infiltration in a peribronchial distribution. Giant cells are prominent.

Subacute or intermittent HP

The noncaseating granulomas are more well formed. There is bronchiolitis with or without organizing pneumonia. Interstitial fibrosis is present.

Chronic HP

There is chronic interstitial inflammation and alveolar destruction (honeycombing). There is dense fibrosis. The pathologic findings of chronic HP that are often associated with a poorer prognosis include the following 3 patterns of fibrosis:

  • Predominantly peripheral fibrosis: in a patchy pattern with architectural distortion and fibroblast foci similar to usual interstitial pneumonia (UIP)
  • Homogeneous linear fibrosis: similar to fibrotic nonspecific interstitial pneumonia (NSIP)
  • Irregular predominantly peribronchiolar fibrosis

Immune Response

Exposure results in the development of circulating immunoglobulin G antibodies that are specific for the offending antigen. This antibody that forms is called the precipitating antibody, and it reacts with the specific putative antigen to form a precipitant. Initially the disease process was thought to be immunecomplex-mediated. However, subsequent studies have demonstrated that cell-mediated immunity is more important.

In the acute phase, there is a local increase in neutrophils in the alveoli and small airways. This is followed by an influx of mononuclear cells which release proteolytic enzymes, prostaglandins, and leukotrienes.

References


Template:WikiDoc Sources

Causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

Hypersensitivity pneumonitis can be caused by exposure to organic antigens that can occur in different occupations. Hundreds of etiological causes can lead to hypersensitivity pneumonitis. Different types of occupations like farmers, poultry/bird handlers, veterinarians, construction workers and textile industry workers are exposed to different kinds of antigens that lead to hypersensitivity pneumonitis.

Causes

  • Hypersensitivity pneumonitis can be caused by exposure to organic antigens that can occur in different occupations.
  • Hundreds of etiological causes can lead to hypersensitivity pneumonitis.
  • Etiology can be divided among various occupations:

Farmers[1]

  • Farmers lung is the most common form of hypersensitivity pneumonitis.
  • It can further be divided based on the type of farming and antigen exposure.
    • Tobacco farmer: Most common antigen are aspergillus and scopulariopsis brevicaulis.
    • Paprika pods farmer: Most common antigen mucor stolonifer.
    • Wine makers: Most common antigen botrytis cincrea.
    • Mushroom cultivaters: Most common antigens are mushroom spores and thermophilic actinomycetes.
    • Potato farming: Most common antigens are thermophilic actinomycetes, T. vulgaris and F. rectivirgula.

Poultry/bird handling[2]

  • Excreta of birds and cattle may induce hypersensitivity pneumonitis.
  • Proteinaceous material on droppings, feathers and serum proteins is dispersed through dust.
  • It can further be divided based on the type of antigen exposure:
    • Poultry workers: Serum proteins from chicken products lead to feather plucker’s disease.
    • Turkey handlers: Most common antigens are serum proteins from turkey products.
    • Duck handlers: Most common antigens are serum proteins from duck feathers products.

Veterinarians

  • Vererinarians are exposed to variety of organic antigens as they work in close proximity to animals.

Constructions workers[3]

  • Construction workers work with a variety of materials which can get infected with mold
  • This can then disperse in fine dust particles carrying mold particles acting as antigens.
  • It can further be divided based on the type of antigen exposure:
    • Wood dust: Most common antigens are Alternaria sp and Bacillus subtilis.
    • Maple bark: Most common antigen is cryptostroma corticale.
    • Composter: Most common antigens are T. vulgaris, and aspergillus.
    • Thatched-roof: Most common antigen is saccharomonospora viridis
    • Esparto dust: Most common antigens aspergillus fumigatus and T. actinomycetes.

Textile workers[4]

  • This exposure can lead to atypical type of hypersensitivity pneumonitis.
  • Diffuse alveolar injury in the form of desquamative interstitial pneumonitis is most common.
  • Exposure to antigens like cotton mill dust, aflatoxin-producing fungus and puffball spores leads to hypersensitivity pneumonitis.

References

  1. Malmberg P, Rask-Andersen A, Rosenhall L (1993). “Exposure to microorganisms associated with allergic alveolitis and febrile reactions to mold dust in farmers”. Chest. 103 (4): 1202–9. PMID 8131466.
  2. Chan AL, Juarez MM, Leslie KO, Ismail HA, Albertson TE (2012). “Bird fancier’s lung: a state-of-the-art review”. Clin Rev Allergy Immunol. 43 (1–2): 69–83. doi:10.1007/s12016-011-8282-y. PMID 21870048.
  3. Alegre J, Morell F, Cobo E (1990). “Respiratory symptoms and pulmonary function of workers exposed to cork dust, toluene diisocyanate and conidia”. Scand J Work Environ Health. 16 (3): 175–81. PMID 2166333.
  4. Lougheed MD, Roos JO, Waddell WR, Munt PW (1995). “Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers. Potential role of mycotoxins”. Chest. 108 (5): 1196–200. PMID 7587416.

Template:WH Template:WS

Differentiating Hypersensitivity pneumonitis from other Disorders

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The differential diagnosis of hypersensitivity pneumonitis is, primarily, a group of diseases known as idiopathic interstitial pneumonia. This group of diseases includes idiopathic pulmonary fibrosis (IPF) (which manifests histologically as usual interstitial pneumonia), idiopathic non-specific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia, among others. There are several important clinical syndromes that occur as a result of inhalation of organic agents but are not true forms of Hypersensitivity Pneumonitis.

Differential Diagnosis

  • HP occurs due to inhalation of organic agents .
  • Several diseases can occur due to this and mimic HP.
  • These disorders are as follows:
    • Inhalation fever:
      • Patients present with fever, chills, headache, and myalgias.
      • There are no pulmonary findings (although mild dyspnea may occur).[1]
      • Onset is 4-8 hours following exposure.
      • No long-term symptoms.
    • Organic dust toxic syndrome:
      • This syndrome occurs due to of exposure to bioaerosols contaminated with toxin-producing fungi (mycotoxins).[2][3][4]
      • Patients present with fever, chills, and myalgias 4-6 hours after exposure. [5]
      • In contrast to inhalation fever, the chest X ray may show diffuse opacities.
      • Bronchiolitis or diffuse alveolar damage may be present on lung biopsy specimens.
      • This is not a true form of HP because no prior sensitization is required.
    • Chronic bronchitis:
      • This is a very severe form of pulmonary disease.
      • Most common respiratory disorder among agricultural workers.
      • The prevalence of chronic bronchitis is much higher at 10%, compared with 1.4% for HP.
    • Exposure to aerosolized Mycobacterium avium complex (MAC):
      • Occurs due to exposure to aerosolized mycobacterium avium complex (MAC).
      • Hot tub lung is a term used to describe these hypersensitivity pneumonitis-like cases because they have generally been associated with hot tub use.
      • The syndrome has been linked to the high levels of infectious aerosols containing MAC organisms found in the water. Whether this syndrome represents a true MAC infection or classic HP remains controversial (Marras, 2005).

By frequency of Interstitial Lung Diseases (Xaubet, 2004):

  1. Idiopathic pulmonary fibrosis (38.6%)
  2. Sarcoidosis (14.9%)
  3. Cryptogenic organizing pneumonia (10.4%)
  4. Interstitial lung disease associated with collagen vascular diseases (9.9%)
  5. Hypersensitivity Pneumonitis (HP) (6.6%)
  6. Unclassified (5.1%)

In alphabetical order:

Restrictive lung disease must be differentiated from other diseases that cause dyspnea, cough, hemoptysis, and fever such as ARDS, bronchitis, hypersensitivity pneumonitis, pneumoconiosis.

Pulmonary Function Test Obstructive Lung Disease Restrictive Lung Disease
TLC
RV
FVC
FEV1 ↓↓
FEV1/FVC N to
MVV

Approach to Lung Disorders

 
 
 
 
 
 
 
 
 
 
 
 
 
Spirometry
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low FEV1/FVC ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal to high FEV1/FVC ratio
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obstructive Lung Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
Restrictive Lung Disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bronchodilator therapy
 
 
 
 
 
 
 
 
 
 
 
 
 
DLCO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increased FEV1
 
 
 
 
 
 
 
No change in FEV1
 
 
 
Normal DLCO
 
 
 
 
 
 
 
Decreased DLCO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asthma
 
 
 
 
 
 
 
COPD
 
 
 
Chest wall disorders
 
 
 
 
 
 
 
Interstitial Lung Disease
 
 


Spirometry Findings in Various Lung Conditions

Spirometry showing Obstructive and Restrictive Lung Disease ([Source:By CNX OpenStax [CC BY 4.0 (http://creativecommons.org/licenses/by/4.0)], via Wikimedia Commons])
Disease Clinical manifestations Diagnosis
Symptoms Physical exam Lab findings Imaging Gold standard
Cough Dyspnea Hemoptysis Fever History/Exposure Cyanosis Clubbing JVD Peripheral edema Auscultation Other prominent findings CXR CT DLCco
Hypersensitivity Pneumonitis + + + +
  • Constitutional symptoms
  • Poorly defined micronodular or diffuse interstitial pattern
  • In chronic form
    • Fibrosis
    • Loss of lung volume
    • Coarse linear opacities
  • Ground-glass opacities or
  • Diffusely increased radiodensities
  • Diffuse micronodules
  • Focal air trapping
  • Mosaic perfusion
  • Occasionaly thin-walled cysts
  • Mild fibrotic changes 
  • Clinical diagnosis
Acute Respiratory Distress Syndrome (ARDS) + +
  • Bilateral pulmonary infiltrates
    • Initially patchy peripheral
    • Later diffuse bilateral
  • Ground glass
  • Frank alveolar infiltrate
  • Bronchial dilatation within areas of ground-glass opacification
  • PaO2 / FiO2 <300
Bronchitis Acute + +/- +
  • Diffuse wheezes
  • High-pitched continuous sounds
  • The use of accessory muscles 
  • Prolonged expiration
  • Rhonchi
  • Rales
  • N/A
  • Normal
  • N/A
  • Clinical diagnosis
Chronic + +
  • A positive history of chronic productive cough 
  • Shortness of breath 
+ + +
  • Prolonged expiration; wheezing
  • Diffusely decreased breath sound
  • Coarse crackles with inspiration
  • Coarse rhonchi
  • N/A
  • Radiolucency
  • Diaphragmatic flattening due to hyperinflation
  • Increased retrosternal airspace on the lateral radiograph
  • N/A
  • N/A
Pneumoconiosis[6] SIlicosis[7][8] + + +/-
  • Occupational history
    • Sandblasting
    • Bystanders
    • Quartzite miller
    • Tunnel workers
    • Silica flour workers
    • Workers in the scouring powder industry
+ + +
  • Small round opacities
    • Symmetrically distributed
    • Upper-zone predominance
  • Diffuse interstitial pattern of fibrosis without the typical nodular opacities in chronic case
  • Nodular changes in lung parenchyma
  • Progressive massive fibrosis
  • Bullae, emphysema
  • Pleural, mediastinal, and hilar changes
Asbestosis
  • Shipyard workers
  • Pipe fitting
  • Insulators
  • Predilection to lower lobes
  • Fine and coarse linear, peripheral, reticular opacities
  • Subpleural linear opacities seen parallel to the pleura
  • Basilar lung fibrosis
  • Peribronchiolar, intralobular, and interlobular septal fibrosis;
  • Honeycombing
  • Pleural plaques.
Berylliosis 
  • Electronic manufactures
  • Hilar adenopathy
  • Increased interstitial markings.
  • Ground glass opacification
  • Parenchymal nodules
  • Septal lines
Byssinosis 
  • Cotton wool workers
  • Diffuse air-space consolidation
  • Pulmonary fibrosis with honeycombing
  • Peri bronchovascular distribution of nodules
  • Ground-glass attenuations
Sarcoidosis + + + +
  • Usually normal
  • Occasional crackles
  • Bilateral hilar lymphadenopathy
  • High-resolution CT (HRCT) scanning of the chest may identify
    • Active alveolitis
    • Fibrosis
Pleural Effusion + + +/- +/- Transudate

Exudate

+/- +/- +/- +/-
  • Peripheral edema, distended neck veins, and S3 gallop suggest congestive heart failure.
  • Edema may also be a manifestation of nephrotic syndrome, pericardial disease, or, when combined with yellow nailbeds, the yellow nail syndrome.
  • Cutaneous changes and ascites suggest liver disease.
  • Lymphadenopathy or a palpable mass suggests malignancy.
Supine
  • Blunting of the costophrenic angle
  • Homogenous increase in density spread over the lower lung fields

Lateral decubitus

  • Free flowing effusion as layers
  • Thickened pleura
  • Mild effusions can aslo be detected
Interstitial (Nonidiopathic) Pulmonary Fibrosis + ++ + + + + +
  • Increased A-a gradient
  • Elevated ESR
  • Serologic testing for ANA, RF, ANCA & ASCA may be positive
  •  Reticular and/or nodular opacities
  • Honeycomb appearance (late finding)
  • Bilateral reticular and nodular interstitial infiltrates
Video-assisted thoracoscopic lung biopsy
Lymphocytic Interstitial Pneumonia[9] + + + + +
  • Increased A-a gradient
  • Polyclonal hypergammaglobulinemia
  • Increased LDH
  • Bibasilar interstitial or micronodular infiltrates
  • Determines the degree of fibrosis
  • Cysts (characterstic)
N Open lung biopsy
Obesity[10][11] + + +
  • X ray findings are often limited due to body habitus
  • CT findings are variable and depends upon severity of obesity
N Clinical
Pulmonary Eosinophilia[12] + + + + Infections + + +
  • Increased A-a gradient
  • Interstitial or diffuse nodular densities
  • Determines extent and distribution of the disease
  • Interstitial infiltrates
  • Cysts and nodules
Biopsy of lesion (skin or lung)
Neuromuscular disease Scoliosis +
  • Postural abnormality
  • In severe scoliosis, the rib cage may press against the lungs making it more difficult to breathe.
  • Accurate depiction of the true magnitude of the spinal deformity can be assessed by supine anteroposterior (AP) and lateral spinal radiographs
  • N/A
N
  • Clinical
  • Radiographs
Muscular dystrophy +
  • Proximal muscle weakness
  • N/A
  • N/A
N
ALS +
  • Muscle weakness
  • Neurological deficit
  • Symptoms begin with limb involvement diue to muscle weakness and atrophy. 
  • Cognitive or behavioral dysfunction
  • Sensory nerves and the autonomic nervous system are generally unaffected
N/A Not significant/diagnostic Not significant/diagnostic
Myasthenia gravis + + H/O of difficulty getting up from chair
  • Extraocular, bulbar, or proximal limb muscles.
  • Breathing as rapid and shallow
  • Respiratory muscle weakness can lead to acute respiratory failure may require immediate intubation.
  • Anti–acetylcholine receptor (AChR) antibody (Ab) test +
  • Thymoma as an anterior mediastinal mass.
  • Thymoma as an anterior mediastinal mass.
N

References

  1. Antonini JM, Lewis AB, Roberts JR, Whaley DA (April 2003). “Pulmonary effects of welding fumes: review of worker and experimental animal studies”. Am. J. Ind. Med. 43 (4): 350–60. doi:10.1002/ajim.10194. PMID 12645092.
  2. Lougheed MD, Roos JO, Waddell WR, Munt PW (November 1995). “Desquamative interstitial pneumonitis and diffuse alveolar damage in textile workers. Potential role of mycotoxins”. Chest. 108 (5): 1196–200. PMID 7587416.
  3. Jagielo PJ, Thorne PS, Watt JL, Frees KL, Quinn TJ, Schwartz DA (July 1996). “Grain dust and endotoxin inhalation challenges produce similar inflammatory responses in normal subjects”. Chest. 110 (1): 263–70. PMID 8681637.
  4. Emanuel DA, Wenzel FJ, Lawton BR (March 1975). “Pulmonary mycotoxicosis”. Chest. 67 (3): 293–7. PMID 46192.
  5. Malmberg P, Rask-Andersen A, Rosenhall L (April 1993). “Exposure to microorganisms associated with allergic alveolitis and febrile reactions to mold dust in farmers”. Chest. 103 (4): 1202–9. PMID 8131466.
  6. Gay SE, Kazerooni EA, Toews GB, Lynch JP, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, Martinez FJ (1998). “Idiopathic pulmonary fibrosis: predicting response to therapy and survival”. Am. J. Respir. Crit. Care Med. 157 (4 Pt 1): 1063–72. doi:10.1164/ajrccm.157.4.9703022. PMID 9563720.
  7. du Bois RM (2006). “Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis”. Clin. Chest Med. 27 (1 Suppl 1): S17–25, v–vi. doi:10.1016/j.ccm.2005.08.001. PMID 16545629.
  8. Neghab M, Mohraz MH, Hassanzadeh J (2011). “Symptoms of respiratory disease and lung functional impairment associated with occupational inhalation exposure to carbon black dust”. J Occup Health. 53 (6): 432–8. PMID 21996929.
  9. Honda O, Johkoh T, Ichikado K, Tomiyama N, Maeda M, Mihara N, Higashi M, Hamada S, Naito H, Yamamoto S, Nakamura H (1999). “Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT”. AJR Am J Roentgenol. 173 (1): 71–4. doi:10.2214/ajr.173.1.10397102. PMID 10397102.
  10. Zammit C, Liddicoat H, Moonsie I, Makker H (2010). “Obesity and respiratory diseases”. Int J Gen Med. 3: 335–43. doi:10.2147/IJGM.S11926. PMC 2990395. PMID 21116339.
  11. O’Neill, Donal (2015). “Measuring obesity in the absence of a gold standard”. Economics & Human Biology. 17: 116–128. doi:10.1016/j.ehb.2015.02.002. ISSN 1570-677X.
  12. de Górgolas M, Casado V, Renedo G, Alen JF, Fernández Guerrero ML (2009). “Nodular lung schistosomiais lesions after chemotherapy for dysgerminoma”. Am. J. Trop. Med. Hyg. 81 (3): 424–7. PMID 19706907.


Template:WikiDoc Sources

Epidemiology and Demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

The incidence and prevalence of hypersensitivity pneumonitis varies depending on various factors like season, occupation etc.Hypersensitivity pneumonitis usually affects patients in fourth to sixth decade of life.The mean age at diagnosis is 53 +/- 14 years.There is no racial predilection to hypersensitivity pneumonitis. Hypersensitivity pneumonitis affects men and women equally. Death due to Hypersensitivity pneumonitis is reported more in men.

Epidemiology and Demographics

Incidence

  • The incidence rate of hypersensitivity pneumonitis varies depending on various factors like season, occupation etc. [1]
    • The incidence of hypersensitivity pneumonitis among farmers is approximately 8 – 540 per 100,000 individuals worldwide.
    • The incidence of hypersensitivity pneumonitis pigeon breeders is approximately 6000 to 21,000 per 100,000 individuals worldwide.

Prevalence

  • The prevalence of hypersensitivity pneumonitis varies based on exposure/occupation.
  • These are as following:
    • Farmers:
      • US: 8-540 cases per 100,000 persons per year among those at risk.[2]
      • UK: 420-3000 cases per 100,000 persons per year among those at risk.[3]
      • France: 4370 cases per 100,000 persons per year among those at risk.[4]
      • Finland: 1400-1700 cases per 100,000 persons per year among those at risk.[5]
    • Pigeon Breeders: 6000-21,000 cases per 100,000 persons per year
    • Bird Fanciers: 20-20,000 cases per 100,000 persons per year

Age

  • Hypersensitivity pneumonitis usually affects patients in fourth to sixth decade of life.
  • The mean age at diagnosis is 53 +/- 14 years.[6]

Race

  • There is no racial predilection to hypersensitivity pneumonitis.

Gender

  • Hypersensitivity pneumonitis affects men and women equally.
  • Death due to Hypersensitivity pneumonitis is reported more in men.[7]

References

  1. Terho EO, Husman K, Vohlonen I (1987). “Prevalence and incidence of chronic bronchitis and farmer’s lung with respect to age, sex, atopy, and smoking”. Eur J Respir Dis Suppl. 152: 19–28. PMID 3499342.
  2. Gruchow HW, Hoffmann RG, Marx JJ, Emanuel DA, Rimm AA (1981). “Precipitating antibodies to farmer’s lung antigens in a Wisconsin farming population”. Am. Rev. Respir. Dis. 124 (4): 411–5. doi:10.1164/arrd.1981.124.4.411. PMID 7027852.
  3. Dalphin JC, Debieuvre D, Pernet D, Maheu MF, Polio JC, Toson B, Dubiez A, Monnet E, Laplante JJ, Depierre A (1993). “Prevalence and risk factors for chronic bronchitis and farmer’s lung in French dairy farmers”. Br J Ind Med. 50 (10): 941–4. PMC 1035525. PMID 8217855.
  4. Depierre A, Dalphin JC, Pernet D, Dubiez A, Faucompré C, Breton JL (1988). “Epidemiological study of farmer’s lung in five districts of the French Doubs province”. Thorax. 43 (6): 429–35. PMC 461305. PMID 3420554.
  5. Terho EO (1990). “Work-related respiratory disorders among Finnish farmers”. Am. J. Ind. Med. 18 (3): 269–72. PMID 2220830.
  6. Hanak V, Golbin JM, Ryu JH (2007). “Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis”. Mayo Clin. Proc. 82 (7): 812–6. doi:10.4065/82.7.812. PMID 17605960.
  7. Adkinson NF. Hypersensitivity Pneumonitis. Middleton’s Allergy: Principles and Practice. 8th Ed. Saunders; 2013.

Template:WH Template:WS

Risk Factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

The incidence and prevalence of hypersensitivity pneumonitis varies depending on various factors like season, occupation etc.Hypersensitivity pneumonitis usually affects patients in fourth to sixth decade of life.The mean age at diagnosis is 53 +/- 14 years.There is no racial predilection to hypersensitivity pneumonitis. Hypersensitivity pneumonitis affects men and women equally. Death due to Hypersensitivity pneumonitis is reported more in men.

Epidemiology and Demographics

Incidence

  • The incidence rate of hypersensitivity pneumonitis varies depending on various factors like season, occupation etc. [1]
    • The incidence of hypersensitivity pneumonitis among farmers is approximately 8 – 540 per 100,000 individuals worldwide.
    • The incidence of hypersensitivity pneumonitis pigeon breeders is approximately 6000 to 21,000 per 100,000 individuals worldwide.

Prevalence

  • The prevalence of hypersensitivity pneumonitis varies based on exposure/occupation.
  • These are as following:
    • Farmers:
      • US: 8-540 cases per 100,000 persons per year among those at risk.[2]
      • UK: 420-3000 cases per 100,000 persons per year among those at risk.[3]
      • France: 4370 cases per 100,000 persons per year among those at risk.[4]
      • Finland: 1400-1700 cases per 100,000 persons per year among those at risk.[5]
    • Pigeon Breeders: 6000-21,000 cases per 100,000 persons per year
    • Bird Fanciers: 20-20,000 cases per 100,000 persons per year

Age

  • Hypersensitivity pneumonitis usually affects patients in fourth to sixth decade of life.
  • The mean age at diagnosis is 53 +/- 14 years.[6]

Race

  • There is no racial predilection to hypersensitivity pneumonitis.

Gender

  • Hypersensitivity pneumonitis affects men and women equally.
  • Death due to Hypersensitivity pneumonitis is reported more in men.[7]

References

  1. Terho EO, Husman K, Vohlonen I (1987). “Prevalence and incidence of chronic bronchitis and farmer’s lung with respect to age, sex, atopy, and smoking”. Eur J Respir Dis Suppl. 152: 19–28. PMID 3499342.
  2. Gruchow HW, Hoffmann RG, Marx JJ, Emanuel DA, Rimm AA (1981). “Precipitating antibodies to farmer’s lung antigens in a Wisconsin farming population”. Am. Rev. Respir. Dis. 124 (4): 411–5. doi:10.1164/arrd.1981.124.4.411. PMID 7027852.
  3. Dalphin JC, Debieuvre D, Pernet D, Maheu MF, Polio JC, Toson B, Dubiez A, Monnet E, Laplante JJ, Depierre A (1993). “Prevalence and risk factors for chronic bronchitis and farmer’s lung in French dairy farmers”. Br J Ind Med. 50 (10): 941–4. PMC 1035525. PMID 8217855.
  4. Depierre A, Dalphin JC, Pernet D, Dubiez A, Faucompré C, Breton JL (1988). “Epidemiological study of farmer’s lung in five districts of the French Doubs province”. Thorax. 43 (6): 429–35. PMC 461305. PMID 3420554.
  5. Terho EO (1990). “Work-related respiratory disorders among Finnish farmers”. Am. J. Ind. Med. 18 (3): 269–72. PMID 2220830.
  6. Hanak V, Golbin JM, Ryu JH (2007). “Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis”. Mayo Clin. Proc. 82 (7): 812–6. doi:10.4065/82.7.812. PMID 17605960.
  7. Adkinson NF. Hypersensitivity Pneumonitis. Middleton’s Allergy: Principles and Practice. 8th Ed. Saunders; 2013.

Template:WH Template:WS

Screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

Screening

References

Template:WH Template:WS

Natural History, Complications, and Prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sargun Singh Walia M.B.B.S.[2]

Overview

If left untreated, patients with hypersensitivity pneumonitis may progress to develop flu like syndrome, cough, fatigue and malaise.Common complications of hypersensitivity pneumonitis include deterioration of lung function, hypoxemia, pulmonary hypertension and heart failure. Prognosis of hypersensitivity pneumonitis is generally excellent, and total lung recovery occurs in most cases but may take several years.

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of hypersensitivity pneumonitis usually develop in within hours if significant exposure occurs.
  • If the exposure to antigen is removed then the symptoms resolve within hours to days.
  • If left untreated, patients with hypersensitivity pneumonitis may progress to develop flu like syndrome, cough, fatigue and malaise.

Complications

  • Common complications of hypersensitivity pneumonitis include:

Prognosis

  • Prognosis of hypersensitivity pneumonitis is generally excellent.
  • Total lung recovery occurs in most cases but may take several years.[3]
  • Surgical lung biopsy can be done to check for fibrosis which is an indicator of poor prognosis.[4]
  • Prediction of prognosis can be done using high resolution CT scan.[5]
  • A study done among old patients suffering from hypersensitivity pneumonitis with no signs of air trapping on CT scan but desaturation with exercise showed poor survival rates.[6]

References

  1. Conca G (May 1972). “[Prevention of male sterility in childhood]”. Minerva Med. (in Italian). 63 (41): 2368–9. PMID 4402194.
  2. Nathan SD (August 2014). “Hypersensitivity pneumonitis and pulmonary hypertension: how the breeze affects the squeeze”. Eur. Respir. J. 44 (2): 287–8. doi:10.1183/09031936.00061214. PMID 25082906.
  3. Wang P, Xu ZJ, Xu WB, Shi JH, Tian XL, Feng RE, Zhu YJ (December 2009). “Clinical features and prognosis in 21 patients with extrinsic allergic alveolitis”. Chin. Med. Sci. J. 24 (4): 202–7. PMID 20120765.
  4. Sahin H, Brown KK, Curran-Everett D, Hale V, Cool CD, Vourlekis JS, Lynch DA (August 2007). “Chronic hypersensitivity pneumonitis: CT features comparison with pathologic evidence of fibrosis and survival”. Radiology. 244 (2): 591–8. doi:10.1148/radiol.2442060640. PMID 17641377.
  5. Hanak V, Golbin JM, Hartman TE, Ryu JH (July 2008). “High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis”. Chest. 134 (1): 133–8. doi:10.1378/chest.07-3005. PMID 18403660.
  6. Lima MS, Coletta EN, Ferreira RG, Jasinowodolinski D, Arakaki JS, Rodrigues SC, Rocha NA, Pereira CA (April 2009). “Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival”. Respir Med. 103 (4): 508–15. doi:10.1016/j.rmed.2008.12.016. PMID 19179061.

Template:WH Template:WS

Diagnosis

Diagnosis

Diagnostic Criteria | History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | MRI | Other Imaging Findings | Other Diagnostic Studies

Treatment

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

See Also

See Also

Template:Respiratory pathology


Template:WikiDoc Sources

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH